Bomedemstat
Imago BioSciences
[]
$imgo imago biosciences presents positive data from ongoing phase 2 study of bomedemstat in advanced myelofibrosis at eha 2022 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities